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Use of domperidone to increase breast milk supply: further consideration of the benefit-risk 
ratio is required 
The statement made by Paul et al. in their systematic review, that “the use of domperidone as a 
galactagogue is worrisome as drug-induced long QT syndrome occurred mostly in women” 1, is 
extremely misleading and not reflective of current evidence. To be clear, there is no evidence that the 
risk of QT interval prolongation associated with the use of domperidone is higher among females.2, 3 
Not discussed by Paul et al. are the results of a recent case-control study investigating the risk of 
serious ventricular arrhythmia and sudden cardiac death associated with the use of domperidone, in 
which an increased risk was only observed among males (adjusted Odds Ratio [aOR] 2.23; 95% 
Confidence Interval [CI] 1.59, 3.13), but not females (aOR 1.25; 95% CI 0.93, 1.67).4 Furthermore, an 
increased risk was only observed among those > 60 years of age (aOR 1.64; 95% CI 1.31, 2.05), and 
not among those ≤ 60 years of age (aOR 1.1; 95% CI 0.35-3.47).4 Also omitted from the review by 
Paul et al.1 is any discussion of a recent randomised, placebo-controlled, double-blind, crossover 
study evaluating the impact of domperidone on QT prolongation among healthy volunteers aged 18-
39 years (representing the likely cohort of breastfeeding mothers).5 In the  study of volunteers, 
domperidone was demonstrated to prolong the QT interval among males, but no difference in QT 
interval was observed among females.5 Taken together, these findings provide evidence of a 
favourable safety profile of domperidone use in breastfeeding mothers.   
In addition the review by Paul et al.1 lacks any consideration of the risks associated with not 
breastfeeding. It is unclear how the benefit-risk profile of domperidone without considering its role in 
maintaining breast milk feeding. We also direct the authors towards a recent article investigating the 
effect of breastfeeding on postpartum depression. In this study, the highest risk of postpartum 
depression was observed among women who had planned to breastfeed and had not been able to 
achieve their goal.6 The authors stressed the necessity to provide expert breastfeeding support to 
women who want to breastfeed, but also the importance of providing compassionate support for 
women who had intended to breastfeed, but who find themselves unable to. This highlights the 
importance of maintaining access to a medication such as domperidone that can assist with the 




management of low milk supply. Despite its use being ‘off-label’, domperidone has a long track 
record of use in lactating mothers,7 with no reports of significant adverse effects. While the use of 
domperidone should never be considered a magic bullet nor as a substitute for effective non-
pharmacological breastfeeding support and encouragement, we strongly feel that it can be used safely 
and effectively where appropriate.2, 3 We firmly believe that the misguided interpretation of the 
current evidence risks subjecting breastfeeding women to the status of therapeutic orphans and 
causing more harm than good.  
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